Buy Ozempic pen 2mg

• as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
• to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and established CV disease
• to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

• Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic^® (3.0%) compared with placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy.
  The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Pen-sharing poses a risk for transmission of blood-borne pathogens
• Hypoglycemia: Patients receiving Ozempic^® in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia
• Acute Kidney Injury Due to Volume Depletion: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to Ozempic^® that could lead to volume depletion, especially during dosage initiation and escalation
• Pulmonary Aspiration During General Anesthesia or Deep Sedation: Ozempic^® delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Ozempic^®

Adverse Reactions

• The most common adverse reactions, reported in ≥5% of patients treated with Ozempic^® are nausea, vomiting, diarrhea, abdominal pain, and constipation

Drug Interactions

• When initiating Ozempic^®, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia

Use in Specific Populations

Discontinue Ozempic^® in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide